Health Sciences Group, Inc. (HESG) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $1.87M is the value of all shares combined. Beta 2.74: the stock has moved about 174% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHealth Sciences Group, Inc. (HESG) trades at $0.0001. Health Sciences Group, Inc. operates in the nutritional supplements and functional foods sector, offering products like sugar substitutes and cardiovascular health formulas. Market cap: $1.87M, Sector: Healthcare.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for HESG: HESG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Health Sciences Group, Inc. (HESG) Healthcare & Pipeline Overview
Health Sciences Group, Inc. develops and distributes nutritional supplements and functional food products, including sugar substitutes and cardiovascular health formulas, primarily through mass market retailers and healthcare professionals. Facing a competitive landscape in the biotechnology sector, the company focuses on proprietary blends and unique product offerings within the United States.
What Is the Investment Thesis for HESG?
Health Sciences Group, Inc. faces significant challenges given its small market capitalization and negative profitability. With a market cap of $1.87M and a negative P/E ratio, the company's financial stability is uncertain. The company's gross margin of 7.0% and profit margin of -15.2% indicate operational inefficiencies. The high beta of 2.74 suggests high volatility relative to the market. Growth prospects hinge on successful product commercialization and expansion into new markets, but these are speculative. Investors should carefully consider the risks associated with investing in a micro-cap company with limited resources and negative earnings.
Based on FMP financials and quantitative analysis
HESG Key Highlights
Market capitalization of $1.87M indicates the company's small size and potential liquidity concerns.
- Negative P/E ratio reflects the company's lack of profitability.
- Gross margin of 7.0% suggests challenges in maintaining competitive pricing and managing production costs.
- Profit margin of -15.2% highlights the company's struggle to achieve profitability.
- Beta of 2.74 indicates high volatility compared to the overall market.
Who Are HESG's Competitors?
HESG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ADXS Ayala Pharmaceuticals, Inc. | $0.60 | 0.00% | $25.7M | — |
| GRTX Galera Therapeutics, Inc. | $17.15 | +9.80% | $3.56B | — |
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $186M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $202M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.68 | -3.94% | $213M | 68 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | 0.00% | $218M | 73 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HESG's Key Strengths?
Proprietary product formulations.
- Established distribution network.
- Brand recognition for specific products.
- Focus on specific health and wellness niches.
What Are HESG's Weaknesses?
Small market capitalization.
- Limited financial resources.
- Negative profitability.
- Dependence on a limited number of products.
What Are the Key Risks for HESG?
Financial-distress signal — its Altman Z-Score of -15.94 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger, more established companies.
- Changing consumer preferences and health trends.
- Regulatory changes affecting the nutritional supplement industry.
- Limited financial resources and negative profitability.
- Risks associated with trading on the OTC market.
What Are HESG's Competitive Advantages?
- Proprietary product formulations (e.g., Sequesterol Advance Cardio Formula).
- Established distribution network through mass market retailers.
- Brand recognition for specific products like Shugr.
What Does HESG Do?
Health Sciences Group Inc., established in 1996 as Centurion Properties Development Corporation, has evolved into a provider of nutritional supplements and functional foods. Initially focused on real estate development, the company transitioned to the health and wellness sector, rebranding as iGoHealthy.com in 2000 before adopting its current name in 2001. The company's core offerings include Shugr, a zero-calorie sugar substitute designed to mimic the taste and baking properties of cane sugar, and Sequesterol Advance Cardio Formula, a proprietary blend of ingredients aimed at supporting cardiovascular health. Additionally, Health Sciences Group offers Aplevia, an antioxidant derived from apple peels, and Edible Sponges, an open-cell hydrocolloid product. These products are distributed through a network of mass market retailers, including mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners. Headquartered in Newport Beach, California, Health Sciences Group operates primarily within the United States, navigating a competitive market landscape to establish its presence in the nutritional supplements and functional foods industry.
What Products and Services Does HESG Offer?
- Develops and markets zero-calorie sugar substitutes.
- Offers cardiovascular health supplements.
- Provides antioxidant products derived from apple peels.
- Manufactures edible hydrocolloid products.
- Distributes products through mass market retailers.
- Sells products through healthcare professionals and practitioners.
How Does HESG Make Money?
- Develops and manufactures nutritional supplements and functional foods.
- Sells products through mass market retailers and healthcare professionals.
- Generates revenue through product sales.
What Industry Does HESG Operate In?
Health Sciences Group operates in the competitive biotechnology industry, specifically within the nutritional supplements and functional foods market. This market is characterized by increasing consumer interest in health and wellness, driving demand for innovative products like sugar substitutes and cardiovascular health supplements. However, the industry is also highly regulated and subject to intense competition from larger, more established players. Health Sciences Group's success depends on its ability to differentiate its products, effectively market to consumers, and navigate the complex regulatory landscape.
Who Are HESG's Key Customers?
- Consumers seeking sugar substitutes.
- Individuals looking for cardiovascular health support.
- Healthcare professionals recommending supplements to patients.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Health Sciences Group, Inc. stands at 2.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.31 means current liabilities exceed short-term assets, a liquidity point worth watching.
Health Sciences Group, Inc. (HESG) Valuation Context
Valued at $1.87M, HESG is classified as a micro-cap stock.
Company Profile
Health Sciences Group, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newport Beach, US. The company is led by CEO Thomas Gaffney. HESG has traded publicly since 2001.
Financial Health
Health Sciences Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.94 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
9 transactions · 0 purchases, 9 sales, 0 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
HESG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
HESG Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Feb 4, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Jan 17, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Jan 16, 2020
HESG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HESG.
Price Targets
Wall Street price target analysis for HESG.
HESG MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HESG; grades run from A+ (80-100) to F (below 30).
Leadership: Thomas Gaffney
CEO
Thomas Gaffney serves as the CEO of Health Sciences Group, Inc. As CEO, he is responsible for the overall strategic direction and operational management of the company, overseeing the development, marketing, and distribution of its nutritional supplements and functional food products. He manages a small team of 2 employees.
Track Record: Given the limited information available, it is difficult to assess Thomas Gaffney's specific achievements and strategic decisions as CEO. The company's financial performance, characterized by negative profitability and a small market capitalization, suggests significant challenges. Further information is needed to evaluate his track record effectively.
HESG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Health Sciences Group, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Longevity of the company's operations (founded in 1996).
- Presence of established products (e.g., Shugr, Sequesterol).
- Distribution through mass market retailers.
- Physical headquarters in Newport Beach, California.
What Investors Ask About Health Sciences Group, Inc. (HESG) — Healthcare
What do analysts say about HESG stock?
As of 2026-03-15, formal analyst ratings for Health Sciences Group, Inc. (HESG) are unavailable, likely due to its small market capitalization and OTC listing. Key valuation metrics such as P/E ratio are not meaningful given the company's negative earnings.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market investments carry higher risks.